TCGA-E2-A10B-01A-11R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 38
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.380
- PROTEIN_SECRETION+0.290
- HEDGEHOG_SIGNALING+0.240
- NOTCH_SIGNALING+0.240
- HEME_METABOLISM+0.200
- MITOTIC_SPINDLE+0.190
- APICAL_SURFACE+0.180
- OXIDATIVE_PHOSPHORYLATION+0.180
- BILE_ACID_METABOLISM+0.140
- INTERFERON_GAMMA_RESPONSE+0.120
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.430
- INFLAMMATORY_RESPONSE-0.260
- HYPOXIA-0.230
- ALLOGRAFT_REJECTION-0.200
- SPERMATOGENESIS-0.190
- KRAS_SIGNALING_UP-0.180
- MYC_TARGETS_V1-0.180
- COAGULATION-0.140
- IL2_STAT5_SIGNALING-0.130
- APOPTOSIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 62F72C1E-2F27-44F1-8A56-31ED4E1E3116 | — | — | 0.608 |
| 2 | EPT0521 | EPN | Posterior Fossa EPN | 0.604 |
| 3 | SRR6013601 | — | cohortA1 | 0.576 |
| 4 | MNG484 | — | — | 0.574 |
| 5 | MNG699 | — | — | 0.574 |
| 6 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.572 |
| 7 | R12 | — | — | 0.571 |
| 8 | R177 | — | — | 0.557 |
| 9 | TCGA-AN-A0XP-01A-11R-A109-07 | — | B | 0.554 |
| 10 | MNG671 | — | — | 0.552 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.060 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |